ATAI Life Sciences N.V. Common Shares (ATAI) Dividend History

Company News

• atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

  atai Life Sciences and Beckley Psytech reported successful Phase 2b clinical trial results for BPL-003, a potential treatment for treatment-resistant depression, demonstrating rapid and durable antidepressant effects with a single intranasal dose and minimal side effects.

  GlobeNewswire Inc.
• 4 Psychedelic Stocks to Consider as Clinical Trials Heat up

  Several biotechnology firms have psychedelic treatments in development, with promising results from clinical trials. The psychedelic market is expected to grow significantly, and most investors are favorable towards psychedelic stocks.

  Investing.com

  Featured Companies: MNMD
• Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment

  A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling.The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues.Some members of the panel, ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: CYBN MNMD PSIL
• Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice

  Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors? Let's find out.

  Zacks Investment Research
• MindMed’s stock soars 51.5% after FDA grants breakthrough designation to LSD therapy for a form of anxiety

  The FDA’s move will speed up development of MindMed’s LSD-based drug as a treatment for generalized anxiety disorder.

  MarketWatch

  Featured Companies: MNMD